Product/Composition:- | Methoxy Polyethylene Glycol-Epoetin Beta Generics |
---|---|
Strength:- | 25–250 mcg |
Form:- | Solution for Injection |
Reference Brands:- | Mircera® (US &EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Methoxy Polyethylene Glycol-Epoetin Beta, marketed as Mircera®, is a long-acting ESA used to treat anemia in CKD patients, both on and off dialysis. Approved in the EU and US, it is available as a solution for injection in prefilled syringes or vials, with extended dosing intervals (biweekly or monthly).
Methoxy Polyethylene Glycol-Epoetin Beta, branded as Mircera®, is an advanced erythropoiesis-stimulating agent (ESA) designed for the treatment of anemia in chronic kidney disease (CKD) patients. Its long half-life enables once-monthly or biweekly dosing, improving compliance and reducing injection frequency. Approved in both the EU and US, Mircera® is widely used in dialysis and non-dialysis CKD populations. Available as prefilled syringes and vials in multiple strengths, it is an essential product in nephrology care. A strategic asset for pharmaceutical B2B partners, it offers opportunities in licensing, distribution, and hospital tenders across regulated markets with growing CKD treatment needs.